Back HCV Disease Progression Fibrosis/Cirrhosis

Fibrosis & Cirrhosis

Can Coffee Help Prevent Liver Fibrosis?

There is good evidence that coffee has a beneficial effect in people at risk for liver fibrosis and there are plausible biological mechanisms to explain why, according to an editorial in the January 27 advance online edition of Hepatology. However, the amount needed to see such an effect may be too high for many people to tolerate, they cautioned.

alt

Read more:

AASLD 2013: Aspirin and Cenicriviroc May Help Reduce Liver Fibrosis

Hepatitis C patients who took low-dose aspirin after liver transplantation experienced slower fibrosis progression, researchers reported at the AASLD Liver Meeting this month in Washington, DC. Two other studies showed that cenicriviroc -- a drug being developed for HIV treatment that blocks both CCR5 and CCR2 cell surface receptors -- had anti-inflammatory and anti-fibrotic activity in mice and rats.

alt

Read more:

IAS 2013: FibroScan Predicts Liver Decompensation and Death Among HIV/HCV Coinfected People

The non-invasive transient elastometry method of estimating liver damage may be a better way to predict which people coinfected with HIV and hepatitis C will progress to decompensated liver cirrhosis and death, researchers reported last week at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013).

alt

Read more:

Coverage of the 2013 AASLD Liver Meeting

HIVandHepatitis.com coverage of the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2013) in Boston, November 1-5, 2013.

Conference highlights include treatment for hepatitis B and C, new direct-acting HCV drugs, interferon-free hepatitis C therapy, management of liver disease complications, HIV/HBV and HIV/HCV coinfection, and prevention and treatment of hepatocellular carcioma.

Full listing by topic

10/30/13

alt

EASL 2013: HIV/HCV Coinfected Patients More Likely to Develop Cirrhosis, but Treatment Lowers Risk

Sustained response to hepatitis C treatment leads to slow regression of liver fibrosis in people with HIV/HCV coinfection, but they remain at elevated risk for liver cirrhosis compared to those without HCV, researchers reported at the EASL International Liver Congress (EASL 2013) last month in Amsterdam.

alt

Read more: